Canadian patent law not a dramatic change, rules Eli Lilly tribunal

The NAFTA tribunal in Eli Lilly v Canada found that a recently developed "promise utility doctrine" in Canadian jurisprudence on pharmaceutical patents did not represent a dramatic change from previous Canadian law, the newly published award reveals.

Unlock unlimited access to all Global Arbitration Review content